Overview
The marketing authorisation for Lamivudine/Zidovudine Teva has been withdrawn at the request of the marketing-authorisation holder.
Lamivudine/Zidovudine Teva : EPAR - Summary for the public
Product information
Lamivudine/Zidovudine Teva : EPAR - Product Information
Latest procedure affecting product information: IB/0028
21/03/2022
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Lamivudine/Zidovudine Teva : EPAR - All Authorised presentations
Product details
- Name of medicine
- Lamivudine/Zidovudine Teva
- Active substance
- lamivudine
- zidovudine
- International non-proprietary name (INN) or common name
- lamivudine
- zidovudine
- Therapeutic area (MeSH)
- HIV Infections
- Anatomical therapeutic chemical (ATC) code
- J05AR01
Pharmacotherapeutic group
Antivirals for systemic useTherapeutic indication
Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.
Assessment history
Lamivudine/Zidovudine Teva : EPAR - Procedural steps taken and scientific information after authorisation